clofibrate has been researched along with Disease Models, Animal in 55 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 7.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| "This study analyzed the effects of the chronic administration of clofibrate, a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on the development and established hemodynamic, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats." | 7.74 | Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats. ( Cruz, A; Moreno, JM; Osuna, A; Rodríguez-Gómez, I; Soler, A; Vargas, F, 2008) |
| "Myotonia was induced in rats with clofibrate given in daily subcutaneous injections of 0." | 7.66 | Myotonia induced with clofibrate in rats. ( Kwieciński, H, 1978) |
| "This study was designed to compare the ability of distal intestinal bypass versus clofibrate administration to prevent the development of atherosclerosis and hypercholesterolemia in monkeys on a standardized atherogenic regimen." | 7.65 | Protective effects of ileal bypass versus administration of clofibrate on experimental hypercholesterolemia and atherosclerosis in monkeys. ( Butts, WH; Curtis, JJ; Scott, HW; Younger, RK, 1976) |
| "Clofibrate was able to decrease Angiotensin II (AngII), AngII AT1-receptor, whereas Ang-(1-7) and AngII AT2-receptor expression increased." | 5.38 | Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2012) |
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 3.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| " Male Wistar rats (weighing 300-350 g) were assigned to the following groups: (1) sham, (2) myocardial ischemia vehicle-treated (MI-V), and (3) myocardial ischemia clofibrate-treated." | 3.81 | PPARα Stimulation Modulates Myocardial Ischemia-induced Activation of Renin-Angiotensin System. ( Cervantes-Pérez, LG; del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2015) |
| " Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats." | 3.80 | PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. ( Newaz, M; Yousefipour, Z, 2014) |
| "This study analyzed the effects of the chronic administration of clofibrate, a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on the development and established hemodynamic, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats." | 3.74 | Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats. ( Cruz, A; Moreno, JM; Osuna, A; Rodríguez-Gómez, I; Soler, A; Vargas, F, 2008) |
| "This study was designed to investigate the effects of two, chemically distinct activators of PPAR-a (clofibrate and WY14643) in a rat model of acute myocardial infarction." | 3.71 | Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size. ( Ellis, BL; Thiemermann, C; Wayman, NS, 2002) |
| "Myotonia was induced in rats with clofibrate given in daily subcutaneous injections of 0." | 3.66 | Myotonia induced with clofibrate in rats. ( Kwieciński, H, 1978) |
| " In the hyperlipemia induced in rats by feeding a high cholesterol diet, Y-9738 [ethyl 2(4-chlorophenyl)-5-ethoxy-4-oxazoleacetate] produced a dose-dependent reduction of serum cholesterol: such hypolipidemic activity was estimated to be about 7 times as great as that of clofibrate." | 3.66 | Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent. ( Kobayakawa, T; Osuga, K; Yasuda, H, 1978) |
| "This study was designed to compare the ability of distal intestinal bypass versus clofibrate administration to prevent the development of atherosclerosis and hypercholesterolemia in monkeys on a standardized atherogenic regimen." | 3.65 | Protective effects of ileal bypass versus administration of clofibrate on experimental hypercholesterolemia and atherosclerosis in monkeys. ( Butts, WH; Curtis, JJ; Scott, HW; Younger, RK, 1976) |
| "Fibrates are potential candidates for treating myopia since they reduced both FDM and the associated axial elongation." | 1.48 | Opposing Effects of PPARα Agonism and Antagonism on Refractive Development and Form Deprivation Myopia in Guinea Pigs. ( Jiao, S; Li, Q; Pan, M; Qu, J; Reinach, PS; Srinivasalu, N; Yan, J; Yang, Y; Zhou, X, 2018) |
| "Clofibrate treatment was shown to concomitantly decrease the liver levels of HNF1α, HNF4α and PCSK9 mRNA, as well as serum PCSK9, TAGs and total cholesterol concentrations in CRF rats." | 1.43 | Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations. ( Rutkowski, B; Sucajtys-Szulc, E; Swierczynski, J; Szolkiewicz, M, 2016) |
| "Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB." | 1.43 | Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, Mde L; Oidor-Chan, VH; Pastelín-Hernández, G; Pérez-Severiano, F; Ramírez-Ortega, Mdel C; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria, E; Torres-Narváez, JC, 2016) |
| "The clofibrate treatment attenuated kidney damage and hepatic oxidative stress while maintaining serum/hepatic sulfatide levels and hepatic CST content in the mice." | 1.38 | Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress. ( Aoyama, T; Hara, A; Kamijo, Y; Kyogashima, M; Nakajima, T; Sheng, X; Sugiyama, E; Takahashi, K; Tanaka, N; Wang, L; Zhang, X, 2012) |
| "Clofibrate was able to decrease Angiotensin II (AngII), AngII AT1-receptor, whereas Ang-(1-7) and AngII AT2-receptor expression increased." | 1.38 | Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2012) |
| "Perfluorooctanoic acid (PFOA) is a potent hepatocarcinogen and peroxisome proliferator (PP) in rodents." | 1.35 | Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. ( Benninghoff, AD; Carpenter, HM; Hendricks, JD; Orner, GA; Pereira, CB; Tilton, SC; Williams, DE, 2008) |
| "Clofibrate treatment restored protein level and improved hepatic function." | 1.34 | Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. ( Burczynski, F; Gong, Y; Jiang, P; Rajaraman, G; Roberts, MS; Shen, H; Wang, G, 2007) |
| "Pretreatment with clofibrate results in partial reversal of changes produced by valproate." | 1.33 | Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. ( Balasubramanian, KA; Eapen, CE; Natarajan, SK; Pullimood, AB, 2006) |
| "Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats." | 1.27 | [Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (45.45) | 18.7374 |
| 1990's | 5 (9.09) | 18.2507 |
| 2000's | 8 (14.55) | 29.6817 |
| 2010's | 16 (29.09) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Idrees, GA | 1 |
| Abuo-Rahma, Gel-D | 1 |
| Aly, OM | 1 |
| Radwan, MF | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Chuppa, S | 1 |
| Liang, M | 1 |
| Liu, P | 1 |
| Liu, Y | 1 |
| Casati, MC | 1 |
| Cowley, AW | 1 |
| Patullo, L | 1 |
| Kriegel, AJ | 1 |
| Pan, M | 1 |
| Jiao, S | 1 |
| Reinach, PS | 1 |
| Yan, J | 1 |
| Yang, Y | 1 |
| Li, Q | 1 |
| Srinivasalu, N | 1 |
| Qu, J | 1 |
| Zhou, X | 1 |
| Ibarra-Lara, L | 3 |
| Sánchez-Aguilar, M | 3 |
| Soria-Castro, E | 3 |
| Vargas-Barrón, J | 1 |
| Roldán, FJ | 1 |
| Pavón, N | 1 |
| Torres-Narváez, JC | 4 |
| Cervantes-Pérez, LG | 5 |
| Pastelín-Hernández, G | 2 |
| Sánchez-Mendoza, A | 4 |
| Yousefipour, Z | 1 |
| Newaz, M | 1 |
| Hong, E | 2 |
| del Valle-Mondragón, L | 4 |
| Pérez-Severiano, F | 4 |
| Ramírez-Ortega, M | 2 |
| Pastelín-Hernández, GS | 2 |
| Sucajtys-Szulc, E | 1 |
| Szolkiewicz, M | 1 |
| Swierczynski, J | 1 |
| Rutkowski, B | 1 |
| Ibarra-Lara, Mde L | 2 |
| Soria, E | 1 |
| Ramírez-Ortega, Mdel C | 1 |
| Oidor-Chan, VH | 1 |
| Tilton, SC | 1 |
| Orner, GA | 1 |
| Benninghoff, AD | 1 |
| Carpenter, HM | 1 |
| Hendricks, JD | 1 |
| Pereira, CB | 1 |
| Williams, DE | 1 |
| Cho, WS | 1 |
| Jeong, J | 1 |
| Choi, M | 1 |
| Park, SN | 1 |
| Han, BS | 1 |
| Son, WC | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Azuma, YT | 1 |
| Nishiyama, K | 1 |
| Morioka, A | 1 |
| Nakajima, H | 1 |
| Takeuchi, T | 1 |
| Nemoto, K | 1 |
| Tanaka, T | 1 |
| Ikeda, A | 1 |
| Ito, S | 1 |
| Mizukami, M | 1 |
| Hikida, T | 1 |
| Gamou, T | 1 |
| Habano, W | 1 |
| Ozawa, S | 1 |
| Inoue, K | 1 |
| Yoshida, M | 1 |
| Nishikawa, A | 1 |
| Degawa, M | 1 |
| Panlilio, LV | 1 |
| Justinova, Z | 1 |
| Mascia, P | 1 |
| Pistis, M | 1 |
| Luchicchi, A | 1 |
| Lecca, S | 1 |
| Barnes, C | 1 |
| Redhi, GH | 1 |
| Adair, J | 1 |
| Heishman, SJ | 1 |
| Yasar, S | 1 |
| Aliczki, M | 1 |
| Haller, J | 1 |
| Goldberg, SR | 1 |
| Sheng, X | 1 |
| Nakajima, T | 1 |
| Wang, L | 1 |
| Zhang, X | 1 |
| Kamijo, Y | 1 |
| Takahashi, K | 1 |
| Tanaka, N | 1 |
| Sugiyama, E | 1 |
| Kyogashima, M | 1 |
| Aoyama, T | 1 |
| Hara, A | 1 |
| Escalante, B | 1 |
| Vargas-Robles, H | 1 |
| Pastelín, G | 1 |
| Sánchez-Mendoza, MA | 1 |
| Wayman, NS | 1 |
| Ellis, BL | 1 |
| Thiemermann, C | 1 |
| Maiguma, T | 1 |
| Fujisaki, K | 1 |
| Itoh, Y | 1 |
| Makino, K | 1 |
| Teshima, D | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| Oishi, R | 1 |
| Savolainen, K | 1 |
| Kotti, TJ | 1 |
| Schmitz, W | 1 |
| Savolainen, TI | 1 |
| Sormunen, RT | 1 |
| Ilves, M | 1 |
| Vainio, SJ | 1 |
| Conzelmann, E | 1 |
| Hiltunen, JK | 1 |
| Natarajan, SK | 1 |
| Eapen, CE | 1 |
| Pullimood, AB | 1 |
| Balasubramanian, KA | 1 |
| Wang, G | 1 |
| Shen, H | 1 |
| Rajaraman, G | 1 |
| Roberts, MS | 1 |
| Gong, Y | 1 |
| Jiang, P | 1 |
| Burczynski, F | 1 |
| Rodríguez-Gómez, I | 1 |
| Cruz, A | 1 |
| Moreno, JM | 1 |
| Soler, A | 1 |
| Osuna, A | 1 |
| Vargas, F | 1 |
| Farina, R | 1 |
| Lovati, MR | 1 |
| Raucci, G | 1 |
| Sirtori, CR | 1 |
| Cavestri, RC | 1 |
| Minatelli, JA | 1 |
| Baldwin, JR | 1 |
| Loh, W | 1 |
| Feller, DR | 1 |
| Newman, HA | 2 |
| Sober, CL | 1 |
| Witiak, DT | 2 |
| Marin-Padilla, M | 1 |
| Mehrotra, K | 1 |
| Morgenstern, R | 1 |
| Lundqvist, G | 1 |
| Becedas, L | 1 |
| Bengtsson Ahlberg, M | 1 |
| Georgellis, A | 1 |
| Doppenberg, EM | 1 |
| Watson, JC | 1 |
| Bullock, R | 1 |
| Gerber, MJ | 1 |
| Zauner, A | 1 |
| Abraham, DJ | 1 |
| Shoda, T | 1 |
| Mitsumori, K | 1 |
| Onodera, H | 1 |
| Toyoda, K | 1 |
| Uneyama, C | 1 |
| Imazawa, T | 1 |
| Hirose, M | 1 |
| Kwieciński, H | 1 |
| Day, CE | 1 |
| Phillips, WA | 1 |
| Schurr, PE | 2 |
| Kobayakawa, T | 1 |
| Osuga, K | 1 |
| Yasuda, H | 1 |
| Gianoulakis, C | 1 |
| Nestruck, AC | 1 |
| Lis, M | 1 |
| Davignon, J | 1 |
| Chrétien, M | 1 |
| Stejskal, R | 1 |
| Itabashi, M | 1 |
| Stanek, J | 1 |
| Hruban, Z | 1 |
| Pick, R | 1 |
| Glick, G | 1 |
| Howard, AN | 1 |
| Magnusson, O | 2 |
| Andersson, I | 1 |
| Nordlund, L | 1 |
| Younger, RK | 1 |
| Curtis, JJ | 1 |
| Butts, WH | 1 |
| Scott, HW | 1 |
| Virág, S | 1 |
| Vértesi, C | 1 |
| Welner, I | 1 |
| Dromgoole, SH | 1 |
| Campion, DS | 1 |
| Peter, JB | 1 |
| Cenedella, RJ | 1 |
| Crouthamel, WG | 1 |
| Yamaguchi, Y | 1 |
| Yamada, K | 1 |
| Kitagawa, S | 1 |
| Kunitomo, M | 1 |
| Betz, E | 1 |
| Quack, G | 1 |
| Mohan, PF | 1 |
| Cleary, MP | 1 |
| Kasiske, BL | 1 |
| O'Donnell, MP | 1 |
| Garvis, WJ | 1 |
| Keane, WF | 1 |
| Morishita, S | 1 |
| Saito, T | 1 |
| Mishima, Y | 1 |
| Mizutani, A | 1 |
| Hirai, Y | 1 |
| Koyama, S | 1 |
| Kawakami, M | 1 |
| Grossberg, SE | 1 |
| Frerman, FE | 1 |
| Lengle, EE | 1 |
| Roch, LA | 1 |
| Hron, WT | 1 |
| Dixon, M | 1 |
| Fitzgerald, JD | 1 |
| Heilman, WP | 1 |
| Dam, H | 1 |
| Schultz, JR | 1 |
| Parkinson, TM | 1 |
| Metelitsa, VI | 1 |
| Matova, EE | 1 |
| Aptekar', SG | 1 |
2 reviews available for clofibrate and Disease Models, Animal
| Article | Year |
|---|---|
Experimental approaches to the prophylaxis and treatment of ischaemic heart disease.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Angina Pectoris; Animals; Biphenyl Compou | 1971 |
Determinants of cholesterol cholelithiasis in man and animals.
Topics: Animals; Bile; Bile Acids and Salts; Chickens; Cholelithiasis; Cholesterol; Cholestyramine Resin; Cl | 1971 |
53 other studies available for clofibrate and Disease Models, Animal
| Article | Year |
|---|---|
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypoli | 2009 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
Topics: Animals; Cardio-Renal Syndrome; Clofibrate; Disease Models, Animal; Fatty Acids; Fibrosis; Gene Expr | 2018 |
Opposing Effects of PPARα Agonism and Antagonism on Refractive Development and Form Deprivation Myopia in Guinea Pigs.
Topics: Animals; Apolipoprotein A-II; Bezafibrate; Biometry; Blotting, Western; Butyrates; Clofibrate; Colla | 2018 |
Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model.
Topics: Animals; Clofibrate; Cytokines; Disease Models, Animal; Hypolipidemic Agents; Inflammation; Inflamma | 2019 |
PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Clofibrate; Disease Models, Ani | 2014 |
PPARα Stimulation Modulates Myocardial Ischemia-induced Activation of Renin-Angiotensin System.
Topics: Angiotensin-Converting Enzyme 2; Animals; Bradykinin; Clofibrate; Disease Models, Animal; Enzyme Act | 2015 |
Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Topics: Actins; Animals; Apolipoprotein B-100; Body Weight; Carrier Proteins; Clofibrate; Disease Models, An | 2016 |
Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction.
Topics: Animals; Clofibrate; Disease Models, Animal; Down-Regulation; Gene Expression Regulation; Inflammati | 2016 |
Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout.
Topics: Aflatoxin B1; Animals; Caprylates; Carcinogenicity Tests; Clofibrate; Cluster Analysis; Dehydroepian | 2008 |
26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Topics: Adenoma, Liver Cell; Administration, Oral; Animals; Carcinogenicity Tests; Carcinogens; Clofibrate; | 2011 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium-mediated desensitisation of contractile machinery.
Topics: Anilides; Animals; Anticholesteremic Agents; Benzamides; Calcium; Clofibrate; Colon; Cyclic AMP-Depe | 2011 |
Super-induced gene expression of the N-methyl-D-aspartate receptor 2C subunit in chemical-induced hypertrophic liver in rats.
Topics: Animals; Clofibrate; Disease Models, Animal; Gene Expression; Hepatomegaly; Liver; Male; Oligonucleo | 2011 |
Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.
Topics: Action Potentials; Animals; Clofibrate; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinic | 2012 |
Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress.
Topics: Acute Disease; Animals; Clofibrate; Disease Models, Animal; Drug Antagonism; Female; Gene Expression | 2012 |
Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension.
Topics: Animals; Biopterins; Clofibrate; Disease Models, Animal; GTP Cyclohydrolase; Hypertension; Hypolipid | 2012 |
Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia.
Topics: Animals; Antioxidants; Catalase; Clofibrate; Disease Models, Animal; Hemodynamics; Lipid Peroxidatio | 2012 |
Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size.
Topics: Animals; Cardiotonic Agents; Clofibrate; Disease Models, Animal; Heart; Hemodynamics; Ligands; Male; | 2002 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric | 2003 |
A mouse model for alpha-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Bile Acids and Salts; Body Weight; Cholesterol; Cholesterol | 2004 |
Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.
Topics: Animals; Anticholesteremic Agents; Clofibrate; Disease Models, Animal; Enzyme Inhibitors; Fatty Live | 2006 |
Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats.
Topics: Animals; Bile Ducts; Blotting, Western; Cholestasis; Clofibrate; Disease Models, Animal; Fatty Acid- | 2007 |
Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats.
Topics: Animals; Blood Pressure; Body Temperature; Body Weight; Clofibrate; Disease Models, Animal; Glucuron | 2008 |
Effects of pantethine on different models of experimental hyperlipidemia in rodents: a comparison with clofibrate.
Topics: Animals; Clofibrate; Disease Models, Animal; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HD | 1982 |
Antilipidemic activity of 4-oxo-functionalized ethyl 6-chlorochroman-2-carboxylate analogs and a related tricyclic lactone in three rat models.
Topics: Animals; Anticholesteremic Agents; Benzopyrans; Chromans; Chromones; Clofibrate; Disease Models, Ani | 1981 |
Morphogenesis of experimental encephalocele (Cranioschisis occulta).
Topics: Animals; Arsenates; Brain; Clofibrate; Cricetinae; Disease Models, Animal; Encephalocele; Microscopy | 1980 |
Effects of peroxisome proliferators and/or hypothyroidism on xenobiotic-metabolizing enzymes in rat testis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arylsulfotransferase; Aspiri | 1997 |
The rationale for, and effects of oxygen delivery enhancement to ischemic brain in a feline model of human stroke.
Topics: Adult; Aged; Aniline Compounds; Animals; Brain; Brain Injuries; Brain Ischemia; Cats; Cerebral Hemor | 1997 |
The relationship between decrease in Cx32 and induction of P450 isozymes in the early phase of clofibrate hepatocarcinogenesis in the rat.
Topics: Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Clofibrate; Connexins; Cytochrome P-450 En | 1999 |
Myotonia induced with clofibrate in rats.
Topics: Action Potentials; Animals; Clofibrate; Disease Models, Animal; Electric Stimulation; Male; Muscles; | 1978 |
Animal models for an integrated approach to the pharmacologic control of atherosclerosis.
Topics: Adamantane; Aniline Compounds; Animals; Arteriosclerosis; Clofibrate; Coturnix; Disease Models, Anim | 1979 |
Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Clofibrate; Disease Models, Animal; Dose-Response Relati | 1978 |
Experimental hyperlipidemia in rats.
Topics: Adipose Tissue; Adrenocorticotropic Hormone; Animals; Blood Pressure; Cholesterol; Clofibrate; Cycli | 1979 |
Experimental porphyria induced by 3-(2,4,6-trimethylphenyl)-thioethyl)-4 methylsydnone.
Topics: Alcohol Oxidoreductases; Animals; Bile Ducts, Intrahepatic; Body Weight; Catalase; Chemical and Drug | 1975 |
Effects of propranolol, minoxidil, and clofibrate on cholesterol-induced atherosclerosis in stumptail macaques (Macaca arctoides).
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Clofibrate; Coronary Disease; Coronary Vessels; Diet, | 1977 |
The baboon as an experimental model in drug testing.
Topics: Animals; Antigen-Antibody Reactions; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Cholestyra | 1977 |
Animal models for screening hypolipidemic agents. I. Response to clofibrate in NMRI-mice of different body-weights.
Topics: Animals; Body Weight; Clofibrate; Disease Models, Animal; Drug Evaluation, Preclinical; Hyperlipidem | 1978 |
Animal models for screening hypolipidemic drugs. III. The response of nicotinic acid and clofibrate in fed and fasted old rats.
Topics: Age Factors; Animals; Clofibrate; Disease Models, Animal; Drug Evaluation, Preclinical; Fasting; Hyp | 1978 |
Protective effects of ileal bypass versus administration of clofibrate on experimental hypercholesterolemia and atherosclerosis in monkeys.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Clofibrate; Diet, Atherogenic; Disease | 1976 |
Combined vessel injuring action of adjuvant arthritis and cholesterol feeding. II. The influence of different types of drugs on the new model of experimental atherosclerosis.
Topics: Animals; Arteriosclerosis; Arthritis, Experimental; Cholesterol, Dietary; Clofibrate; Disease Models | 1976 |
Myotonia induced by clofibrate and sodium chlorophenoxy isobutyrate.
Topics: Clofibrate; Disease Models, Animal; Muscle Contraction; Muscles; Myotonia | 1975 |
Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Topics: Animals; Clofibrate; Dietary Fats; Disease Models, Animal; Glycerol; Glycerophosphates; Glycolates; | 1976 |
Atherosclerosis mouse model induced by a high-cholesterol diet supplemented with beta-aminopropionitrile: effects of various anti-atherosclerotic agents on the biochemical parameters.
Topics: 4-Aminobenzoic Acid; Aminopropionitrile; Animals; Aorta; Arteriosclerosis; Body Weight; Cholesterol; | 1990 |
Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
Topics: Animals; Arteriosclerosis; Clofibrate; Clofibric Acid; Disease Models, Animal; Hypolipidemic Agents; | 1990 |
Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Clofibrate; Clofibric Acid; Dehydroepiandrosterone; Disease Mod | 1989 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
[Strains and species differences in experimental hyperlipidemia].
Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic | 1986 |
Viral infection and lipemia: a problem of disordered host physiology.
Topics: Animals; Carbon Dioxide; Chick Embryo; Clofibrate; Disease Models, Animal; Encephalitis; Encephaliti | 1974 |
Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
Topics: Animals; Anticholesteremic Agents; Benzene Derivatives; Benzofurans; Benzopyrans; Carboxylic Acids; | 1973 |
Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs.
Topics: Animals; Carboxylic Acids; Cholesterol; Clofibrate; Disease Models, Animal; Fasting; Hyperlipidemias | 1972 |
[Experimental lipoidosis of the aorta in rabbits with endogenous hypercholesteremia and without anisotropic adiposis of the liver].
Topics: Adipose Tissue; Aminocaproates; Animals; Aorta; Cholesterol; Clofibrate; Dietary Fats; Disease Model | 1971 |